An SVC stent for superior vena cava syndrome is a self-expanding metal mesh tube placed inside the large vein when a tumour presses on it or blocks it, so blood can flow back to the heart. It is mostly used for people with lung cancer or lymphoma whose face and neck swell and who feel short of breath. The British Society of Interventional Radiology (BSIR) says symptoms usually start to improve within minutes of the stent being deployed.
The Japan Interventional Radiology in Oncology Study Group (JIVROSG) tested stenting in a phase II trial and a phase III randomized trial, and in phase III the stent group had clearly better symptom scores than the control group. This article covers the Japanese trial numbers, a 2,249-patient international analysis, the procedure and recovery, and what to prepare before visiting a hospital in Japan.
Treatment status · An interventional radiology procedure performed in Europe, the UK and Japan. Based on their phase III randomized trial, the Japanese investigators concluded it may be accepted as a standard treatment for symptom management. This article is general information, not a recommendation for any treatment.
Why superior vena cava syndrome happens
The superior vena cava (SVC) is the large vein that collects blood from the head, neck, arms and upper chest and returns it to the heart. It runs through the middle of the chest between the lungs and lymph nodes, so a tumour or enlarged lymph nodes there can easily squeeze it. When blood cannot get back to the heart, it pools in the upper body and causes symptoms.
CIRSE, the European interventional radiology society, names a malignant tumour as the usual cause. In the international analysis below, 2,015 of the 2,237 patients with a known cause, about 90%, had cancer. Lung cancer and lymphoma are typical, and scarring or clots around a long-term central venous line can also be responsible. Read more about these lines in our chemoport placement guide.
- Shortness of breath and a heavy feeling in the chest
- Swelling of the face, neck or arms
- Headache, dizziness and cough
- Enlarged veins on the neck, chest and arms
What the Japanese phase III trial showed
JIVROSG ran two trials in a row for people with vena cava syndrome caused by cancer. A phase II trial (JIVROSG-0402) checked safety and effect first, and a phase III randomized trial (JIVROSG-0807) then compared a stent group with a control group. The results were published in Supportive Care in Cancer in 2019.
| Trial | Patients | Main results |
|---|---|---|
| Phase II (JIVROSG-0402) | 28 patients who received a stent | Median symptom score fell from 10.50 before the procedure to 3.00 within 14 days. Technical success 96.4%, technical feasibility 100% |
| Phase III randomized (JIVROSG-0807) | 32 patients, 16 per group | Stent group significantly superior on the area under the symptom score curve |
Figures as reported in the abstract of Takeuchi et al., Supportive Care in Cancer 2019;27:1081–1088.
The symptom score fell from 10.50 to 3.00, less than a third of the starting level. The investigators wrote that stent placement significantly improved the symptoms of vena cava syndrome and may become a standard treatment for symptom management. Grade 3 or higher treatment-related adverse events occurred in 14.3% of phase II patients.
Results from 2,249 patients worldwide
A UK team pooled 54 studies with 2,249 patients and published the analysis in CardioVascular and Interventional Radiology in 2022. Both cancer and non-cancer causes were included, but about 90% of the patients had cancer.
| Measure | Result | What it means |
|---|---|---|
| Technical success | 96.8% | Stent placed correctly where intended |
| Clinical success | 92.8% | Swelling and breathlessness improved |
| Vein kept open (patency) | 98.0% at 1 month, 94.0% at 12 months | Most veins still flow well after a year |
| Complications | Mean 5.78% | Varied widely between studies |
| Re-intervention | Mean 9.11% | A narrowed stent can be reopened |
Aung et al., CardioVascular and Interventional Radiology 2022;45(9):1236–1254. Patency was 95.6% at 3 months and 93.7% at 6 months.
The authors concluded that stenting is a safe and effective option for SVC syndrome of all causes. Relieving symptoms first makes it easier to continue chemotherapy or radiotherapy in better condition. Local treatment for the lung tumour itself is covered in our lung cancer RFA guide.
How SVC stenting is done
It is a minimally invasive procedure: a thin tube is passed into a vein under X-ray guidance, with no surgical incision. Our interventional radiology (IVR) guide explains this approach in general. According to The Christie, a UK cancer centre, the time in the procedure room is about 1 hour 30 minutes.
| Step | What happens |
|---|---|
| Preparation | Blood tests, review of blood thinners, explanation and consent |
| Anaesthesia | You lie on the table with blood pressure, heart rhythm and oxygen monitored; local anaesthetic at the puncture site |
| Access | A 3 mm sheath is placed in a vein in the neck or groin and the narrowing is found on X-ray |
| Stent | The blockage is crossed with a wire and the stent is opened, sometimes with a small balloon |
| Finish | Contrast images confirm flow, the tube is removed and the vein is pressed until bleeding stops |
Based on CIRSE patient information and The Christie leaflet. Actual steps follow each hospital's protocol.
Recovery and managing side effects
CIRSE says symptoms should stop within 48 hours of stent placement. Patients usually stay one night and most go home the next day. After neck access you sit upright for an hour, and after groin access you lie flat for an hour. Many people take blood-thinning medicine for 1–2 weeks so clots do not form in the stent; the length depends on the stent type and your condition.
| Possible event | How it is managed |
|---|---|
| Bruising or bleeding at the puncture site | Occasional; usually settles with pressure |
| Sudden return of blood to the heart | Rarely causes breathlessness or fluid on the lungs, so heart and breathing are watched after the procedure |
| Heart rhythm changes | Usually settle on their own; the heart is monitored throughout |
| Stent narrowing later | Report new face or arm swelling; the stent can be reopened |
After discharge, contact the hospital if the face or arms start to swell again, or if the puncture site becomes warm or leaks. The Christie notes that most people get long-lasting relief.
What to prepare for a hospital in Japan
In Japan, the radiology (IVR) teams of cancer hospitals perform this procedure. JIVROSG, which ran the phase III trial above, is the main research group, and the radiology and IVR team at Aichi Cancer Center published a 2024 review of vena cava stent features and technique in the Japanese Journal of Interventional Radiology. Stent types and billing differ by hospital, so check in advance.
- Your most recent contrast chest CT (original image files on disc) and the report
- The biopsy-confirmed cancer type and records of chemotherapy and radiotherapy so far
- Platelet and clotting test results and a full medicine list, especially blood thinners
- Any contrast allergy, and whether you have a central line or chemoport in the chest
- Dates and photos of the face and neck swelling, and how breathless you are when lying down
If breathlessness makes it hard to lie flat, tell the team early so they can plan your position and sedation. When symptoms worsen quickly, the procedure may be scheduled as an emergency.
Questions to ask your doctors
- Are my symptoms the kind a stent can relieve quickly?
- Will you go through the neck or the groin?
- When can I continue chemotherapy or radiotherapy after the stent?
- How long will I take blood thinners?
- If the stent narrows again, how will you reopen it?
FAQ
How quickly does an SVC stent relieve superior vena cava syndrome?
BSIR says symptoms usually start to improve within minutes of deployment, and CIRSE says they should stop within 48 hours. In the Japanese phase II trial, symptom scores fell sharply within 14 days.
Is general anaesthesia needed?
Most procedures use local anaesthetic at the puncture site while you stay awake, with sedation if needed.
How long is the hospital stay?
The Christie leaflet says patients stay overnight and most go home the next day, unless other treatment is needed.
Does the stent stay in for life?
Yes, it stays inside the vein. In the international analysis, 94.0% of veins were still open at 12 months, and a narrowed stent can be reopened.
Related: Image-guided biopsy and drainage · TAE transarterial embolization
This article summarizes overseas official sources and studies as general information and is not medical advice. Please discuss treatment choices with the medical team who examines you.
Sources (checked November 5, 2026)
- Takeuchi Y, Arai Y, Sone M, et al. Evaluation of stent placement for vena cava syndrome: phase II trial and phase III randomized controlled trial. Supportive Care in Cancer. 2019;27:1081–1088. (JIVROSG-0402, JIVROSG-0807)
- Aung EY, Khan M, Williams N, Raja U, Hamady M. Endovascular stenting in superior vena cava syndrome: a systematic review and meta-analysis. CardioVascular and Interventional Radiology. 2022;45(9):1236–1254.
- CIRSE. Vena cava stenting. Patient information.
- British Society of Interventional Radiology. Superior vena cava stenting. Patient information leaflet.
- The Christie NHS Foundation Trust. Superior vena cava (SVC) stent. Patient information.
- Murata S, Inaba Y, Sato Y, et al. (Aichi Cancer Center). Vena cava stent. Japanese Journal of Interventional Radiology. 2024;39(1):2–7 (Japanese-language source).